Executive Medical Director – Global Clinical Lead, Hematology/Oncology

Kaye/Bassman is leading a high-visibility search for an Executive Medical Director / Global Clinical Lead to drive a late-stage Phase 3 hematology program in myeloid malignancies (AML/MDS/MPN) for a global biopharma
This is a rare opportunity for a hematologist-oncologist or medical oncologist with Phase 3 leadership experience to own clinical strategy end-to-end: from pivotal execution through registration (NDA/MAA/BLA) and into launch planning, with direct FDA interaction and Advisory Committee exposure.
What you’ll own
Clinical strategy for a Phase 3 program in myeloid malignancies, from pivotal execution through registration and toward launch
Leadership of the global development team across the US, EU, and Asia
Go/no-go and labeling-critical decisions
Clinical science interactions with FDA and other health authorities, including Advisory Committee preparation
Close partnership with Medical Affairs and senior Commercial leadership
Direct reporting line to the Head of Clinical Development, with scope to expand into additional indications or earlier-stage programs
What you bring
MD or MD/PhD (U.S. clinical training preferred, not required)
10+ years in pharmaceutical/biotech clinical research, including Phase 1–4 clinical development
Phase 3 leadership experience in hematology or oncology — hematologic malignancies (AML, MDS, MPN, lymphoma, myeloma) strongly preferred
Experience with NDA/MAA/BLA submissions and regulatory health authority interactions
Experience leading global, matrixed development teams
Large pharma experience preferred; candidates with a mix of large pharma and biotech backgrounds are encouraged to apply
Strong executive presence with the ability to influence senior clinical and commercial leadership